1. Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey.
- Author
-
Zhang, Xin, Shi, Ju-Fang, Liu, Guo-Xiang, Ren, Jian-Song, Guo, Lan-Wei, Huang, Wei-Dong, Shi, Lin-Mei, Ma, Yi, Huang, Hui-Yao, Bai, Ya-Na, Liao, Xian-Zhen, Mao, A-Yan, Sun, Xiao-Jie, Zhu, Xin-Yu, Zhou, Qi, Gong, Ji-Yong, Zhou, Jin-Yi, Liu, Yu-Qin, Mai, Ling, and Song, Bing-Bing
- Subjects
RESEARCH ,CLINICAL pathology ,CONFIDENCE intervals ,ACQUISITION of data methodology ,CANCER chemotherapy ,LUNG tumors ,HOSPITAL costs ,RETROSPECTIVE studies ,MEDICAL cooperation ,SURVEYS ,CANCER patients ,DESCRIPTIVE statistics ,MEDICAL records ,ECONOMIC aspects of diseases ,ODDS ratio ,HEALTH care rationing - Abstract
Background: Lung cancer is the most prevalent cancer, and the leading cause of cancer-related deaths in China. The aim of this study was to estimate the direct medical expenditure incurred for lung cancer care and analyze the trend therein for the period 2002–2011 using nationally representative data in China Methods: This study was based on 10-year, multicenter retrospective expenditure data collected from hospital records, covering 15,437 lung cancer patients from 13 provinces diagnosed during the period 2002–2011. All expenditure data were adjusted to 2011 to eliminate the effects of inflation using China's annual consumer price index. Results: The direct medical expenditure for lung cancer care (in 2011) was 39,015 CNY (US$6,041) per case, with an annual growth rate of 7.55% from 2002 to 2011. Drug costs were the highest proportionally in the total medical expenditure (54.27%), followed by treatment expenditure (14.32%) and surgical expenditure (8.10%). Medical expenditures for the disease varied based on region, hospital level, type, and stage. Conclusion: The medical expenditure for lung cancer care is substantial in China. Drug costs and laboratory test are the main factors increasing medical costs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF